OBJECTIVEdMetabolic memory, in which past hyperglycemia could affect future retinopathy, is a potential issue in studying the relationship between glycemia and retinopathy. We examined retrospectively if mean "metabolic memory-free" glycosylated hemoglobin A1C (HbA 1c ) values covering total diabetes duration could predict retinopathy in younger-onset type 1 diabetes mellitus (T1DM).
T he metabolic memory for glycemia, in which past hyperglycemia could be a risk factor for future retinopathy (1) , might affect evaluation of the influence of glycosylated hemoglobin A1C (HbA 1c ) values on retinopathy if there were periods during the diabetes duration in which HbA 1c values were unknown. Observing "metabolic memory-free" type 1 diabetes mellitus (T1DM) patients with continuous HbA 1c data just after onset may avoid this effect. We studied if mean HbA 1c values could predict retinopathy at 20 years after onset in selected younger T1DM patients minimally affected by hypertension and dyslipidemia. When the mean of the yearly mean HbA 1c values (mA1C) between year N and year 20 after onset was denoted by mA1C (Nth-20th year), the mA1C for the entire 20 years was indicated by mA1C(1st-20th year) and calculated as real data. If each patient had a full 3 years of duration at entry without HbA 1c data during that period, then the mA1C for the remaining observation period (4th-20th year) was indicated by mA1C(4th-20th year); with 6 and 9 years of duration, the mA1Cs for the remaining observation period were indicated by mA1C (7th-20th year) and mA1C(10th-20th year), respectively. We calculated those in simulation by masking the HbA 1c data during the first 3, 6, and 9 years after onset from the real observed data of 20 years.
RESEARCH DESIGN AND
We studied whether real mA1C(1st-20th year) data could predict retinopathy at year 20, and whether the capacity diminished with the length of the period without HbA 1c data following onset using mA1C(4th-20th year), mA1C(7th-20th year), and mA1C(10th-20th year) in simulation. Furthermore, we examined the difference of the transitions of the yearly mean HbA 1c values for the 20-year period between the year-20 retinopathy-positive and retinopathy-negative groups.
The Wilcoxon rank sum test was performed using JMP version 10.0.0 (SAS, Cary, NC). Two-sided P , 0.05 was considered significant.
RESULTSdThe mean age of 15 patients (6 males, 9 females) who fulfilled the criteria was 20.3 years (range 5-28; SD 67.7) at onset. The mean duration at first visit to the center was 2.9 months (range 0-11; SD 62.8).
Of these 15 patients, 5 were retinopathypositive (all showed nonproliferative retinopathy) and 10 were retinopathy-negative at the 20-year follow-up. The values of mA1C(1st-20th year) were well-divided between the two groups ( Fig. 1A, top 
In cases of simulated mA1C(4th-20th year), mA1C(7th-20th year), and mA1C(10th-20th year), the differences seemed to lessen gradually between the positive and negative groups at year 20 ( Fig. 1B-D, top) . There was no significant difference between the two groups in mA1C(10th-20th year), which seemed to have no capacity for predicting year-20 retinopathy (Fig. 1D, top) . The longer the period of unknown HbA 1c data following onset, the lower the capacity of mA1C to predict 20-year retinopathy seemed to become. This could be explained by the difference of the transitions of the yearly mean HbA 1c values between the two groups over the course of 20 years. In the earlier period, these values were higher in the retinopathypositive group, but they gradually decreased until there was no significant difference between groups (Fig. 1A, bottom) .
We obtained nearly complete yearly mean HbA 1c values without estimation, except for 2 values out of 300 values in 15 patients for the 20 years. Over the 20 years, we detected no cases of severe anemia. All patients were normotensive (systolic blood pressure ,140 mmHg and diastolic blood pressure ,90 mmHg) and normolipidemic at their first visit without any drug treatment. At year 20, only one patient was undergoing drug care.diabetesjournals.org DIABETES CARE, VOLUME 36, NOVEMBER 2013 3813 treatment for hypertension or dyslipidemia, or both.
CONCLUSIONSdWe demonstrated that mean HbA 1c values had a substantial capacity to predict retinopathy at year 20 after onset in our selected younger T1DM patients when we used metabolic memory-free HbA 1c data covering the entire duration of diabetes. This suggests that total glycemic exposure in T1DM might have a greater potential for predicting retinopathy than previously reported (2) . Furthermore, the longer the period with unknown HbA 1c data following onset, the lower the predictive capability of mean HbA 1c values for the remaining period seemed to become. This was because of the nonuniform transitions of yearly mean HbA 1c values between the year-20 retinopathypositive and retinopathy-negative groups. If one began to observe patients who already had long durations of diabetes at a given study entry, the previous unknown higher HbA 1c values might cause underestimation of the total glycemic exposure in the retinopathy-positive group, thus providing a less accurate picture of the relationship between glycemic exposure and retinopathy (2) . The use of only partial, not whole, post-midcourse HbA 1c data of patients with long durations of diabetes might distort evaluation of the true influence of glycemia on diabetes complications.
Because of our low number of subjects, further investigation is needed to confirm the results. However, we scrupulously selected younger T1DM patients with continuous HbA 1c data for the entire duration of their diabetes after clear onsets. We also tried to maximize the relative uniformity of conditions in evaluating glycemia and retinopathy among patients, because that was critical for this study. HbA 1c values measured by six different instruments might be another limitation, although we used values measured only in our institution with careful calibration between instruments. Retinopathy evaluation by ophthalmoscopy, not photography, could be another limiting factor. Because evaluation was performed only by ophthalmologists in our center in the same manner, a relatively uniform level of accuracy in detection could be expected for all patients, including the retinopathypositive and retinopathy-negative patients at year 20. Also, the substantially contemporaneous follow-up periods (first visits within a short span of 3 years) used may improve the uniformity of the evaluations of glycemia and retinopathy.
This study could help to promote more accurate investigation of the relationship between hyperglycemia and retinopathy in T1DM, and it demonstrates the importance of using HbA 1c data from the total, not partial, diabetes duration to exclude the metabolic memory effect.
